Around the world, publicly-funded healthcare systems face a common challenge: ensuring limited resources are allocated to treatments offering the best value for patients and taxpayers. Without robust ...

The recommendation of betula verrucosa is the first NICE approval for an under-the-tongue immunotherapy for these conditions. Unlike conventional treatments that merely mask symptoms, this ...

Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

The technologies, which have been conditionally recommended in draft guidance, can help detect vertebral fragility fractures (VFFs) on medical images taken for unrelated condition. This means they ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

Updated guideline to increase access to treatments for early-stage chronic heart failure could reduce deaths and hospital admissions by thousands Around 3,000 deaths and 5,500 hospital admissions in ...

Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults. Last reviewed: ...

Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults. Last ...

This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk ...

Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non‑small‑cell lung cancer after complete tumour resection in adults. Last reviewed: 26 February 2025 ...

Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults. Last ...